EMEA-003534-PIP01-23
Submitted by Anonymous (not verified) on 11 June 2025 - 10:51
EMEA-003534-PIP01-23
EMEA-003530-PIP01-23
Submitted by Anonymous (not verified) on 11 June 2025 - 10:27
EMEA-003530-PIP01-23
Human medicines European public assessment report (EPAR): Zostavax, shingles (herpes zoster) vaccine (live), Date of authorisation: 19/05/2006, Revision: 33, Status: Withdrawn
Submitted by Anonymous (not verified) on 11 June 2025 - 9:55
Human medicines European public assessment report (EPAR): Zostavax, shingles (herpes zoster) vaccine (live), Date of authorisation: 19/05/2006, Revision: 33, Status: Withdrawn
EMEA-003485-PIP01-23
Submitted by Anonymous (not verified) on 11 June 2025 - 9:50
EMEA-003485-PIP01-23
EMEA-003481-PIP01-23
Submitted by Anonymous (not verified) on 11 June 2025 - 9:33
EMEA-003481-PIP01-23
EMEA-003478-PIP01-23
Submitted by Anonymous (not verified) on 11 June 2025 - 9:16
EMEA-003478-PIP01-23
EMEA-003465-PIP01-23
Submitted by Anonymous (not verified) on 11 June 2025 - 9:09
EMEA-003465-PIP01-23
EMEA-002958-PIP01-21-M01
Submitted by Anonymous (not verified) on 10 June 2025 - 16:51
EMEA-002958-PIP01-21-M01
Opinion/decision on a Paediatric investigation plan (PIP): Koselugo, Selumetinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: P/0134/2024
Submitted by Anonymous (not verified) on 10 June 2025 - 16:43
Opinion/decision on a Paediatric investigation plan (PIP): Koselugo, Selumetinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: P/0134/2024
Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, Mirikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0130/2024
Submitted by Anonymous (not verified) on 10 June 2025 - 16:33
Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, Mirikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0130/2024